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Abstract
Background and Objectives—Over 12% of U.S. adults report past-year cannabis use, and 
among those who use daily, 25% or more have a cannabis use disorder. Use is increasing as legal 
access expands. Yet, cannabis use is not routinely assessed in primary care, and little is known 
about use among primary care patients and relevant demographic and behavioral health subgroups. 
This study describes the prevalence and frequency of past-year cannabis use among primary care 
patients assessed for use during a primary care visit.
Methods—This observational cohort study included adults who made a visit to primary care 
clinics with annual behavioral health screening, including a single-item question about frequency 
past-year cannabis use (March 2015-February 2016; n=29,857). Depression, alcohol and other 
drug use were also assessed by behavioral health screening. Screening results, tobacco use, and 
diagnoses for past-year behavioral health conditions (e.g., mental health and substance use 
disorders) were obtained from EHRs.
Corresponding Author: Gwen Lapham, PhD, MPH, MSW, Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, 
Suite 1600, Seattle, WA 98101, Phone: 206-287-2021, lapham.g@ghc.org. 
CONFLICT OF INTEREST DISCLOSURES
Dr. McCarty was the principal investigator on research service agreements with Purdue Pharma and Alkermes. No other disclosures to 
report.
Pulished in final edited form as:
J Am Board Fam Med. 2017 ; 30(6): 795–805. doi:10.3122/jabfm.2017.06.170062.
Results—Among patients who completed the cannabis use question (n=22,095; 74% of eligible 
patients), 15.3% (14.8–15.8%) reported any past-year use: 12.2% (11.8%–12.6%) less than daily 
and 3.1% (2.9%–3.3%) daily. Among 2,228 patients 18–29 years, 36.0% (34.0%–38.0%) reported 
any cannabis use and 8.1% (7.0%–9.3%) daily use. Daily cannabis use was common among men 
18–29 who used tobacco or screened positive for depression: 25.5% (18.8%–32.1%) and 31.7% 
(23.3%–40.0%), respectively.
Conclusions—Cannabis use was common in adult primary care patients, especially among 
younger patients and those with behavioral health conditions. Results highlight the need for 
primary care approaches to address cannabis use.
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INTRODUCTION
Cannabis is the most commonly used drug in the United States, after alcohol and tobacco.1 
As of 2013, 13% of U.S. adults – nearly 20 million people - used cannabis in the past year, 
and over 8 million used daily.1 Nearly 3 in 10 adults who use cannabis have a cannabis use 
disorder, defined as meeting 2 or more of 11 substance use disorder criteria (Table 1).2,3 The 
prevalence of a cannabis use disorder increases with increasing frequency of use 1,3,4
With expanding legalization of cannabis use, the number of cannabis users—and daily 
cannabis users at greatest risk for a cannabis use disorder4—is projected to grow over the 
next 5–10 years.5 Medical cannabis use is now legal in 29 states and nonmedical use in 8, 
including California, and the District of Columbia, with more states considering 
legalization.6,7 Sale of cannabis for nonmedical use, including dried plant materials and 
increasingly, a wide variety of highly-potent cannabinoid products, began in 2014 in 
Colorado and Washington State, with restricted start-up sales beginning in 2015 for Oregon 
and in 2016 for Alaska.8,9 Yet, to our knowledge, cannabis use is not routinely assessed in 
U.S. primary care settings. As cannabis use increases, primary care providers may want to 
know when patients use cannabis regularly.10
No U.S. study has evaluated the population-based prevalence of patient-reported cannabis 
use among primary care patients, particularly in a state where nonmedical use is legal. 
Kaiser Permanente Washington (formerly Group Health), an integrated health system in 
Washington State, is currently implementing routine behavioral health screening as part of 
behavioral health integration in primary care clinics. At the request of providers, in the 
context of state legalization, a question about cannabis use was added to the behavioral 
health screen before a question about illicit drug use.11 The purpose of this study was to 
assess the prevalence and frequency of self-reported past-year cannabis use among primary 
care patients. Specifically, the prevalence and frequency of cannabis use is described in the 
total primary care sample, as well as within demographic and behavioral health subgroups. 
The study also addresses implications for primary care for patients who use cannabis.
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METHODS
Setting
Kaiser Permanente Washington, a nonprofit health care system with 25 primary care sites 
throughout Washington State, implemented annual behavioral health screening, including a 
question about cannabis use, for adults in 3 primary care sites starting in March 2015. 
Implementation of behavioral health screening was staggered across the three sites, which 
were chosen for their receptivity to implementation and community representativeness. The 
sites, spread across 90 miles in Western Washington, enrolled about 80,000 patients (17,000 
– 37,000 per clinic). Site A initiated behavioral health screening in March 2015 (2 of 3
primary care clinics within the site); Site B initiated in early October (2 of 4 clinics); and 
Site C initiated in late October in (1 of 2 clinics). Staff at each site assisted with work flow 
development for behavioral health screening and met regularly to review and improve 
screening prevalence (target 80%). Electronic health record (EHR) prompts alerted staff 
when patients were due for screening. After check-in, patients completed a 7-item 
behavioral health screen (described below) on paper. Medical assistants typically entered 
results into the EHR and shared the results with the provider prior to the patient-provider 
visit.
Data Source and Study Population
This observational cohort study obtained study data, including behavioral health screen 
results and patient demographic and clinical characteristics, from Kaiser Permanente 
Washington’s EHR. Patients 18 years and older were included if they attended an in-person 
visit with a primary care provider in one of the 3 participating primary care sites from study 
start (i.e., after initiation of screening at each site) through mid-February 2016. Patients with 
EHR documentation of a response to the cannabis question during the study period, 
indicating question completion, comprised the study sample. This study received approval 
and waivers of consent and HIPAA authorization from the Kaiser Permanente Washington 
Health Research Institute Institutional Review Board.
Measures
The 7-item Behavioral Health Screen
Past-Year Cannabis Use: The single-item cannabis use question, modeled after the third 
question of the World Health Organization’s (WHO) 10-item AUDIT,12 asked about the 
frequency of past-year cannabis use (i.e., “How often in the past year did you use 
marijuana?” - “never”, “less than monthly”, “monthly”, “weekly”, and “daily or almost 
daily”). The response options are identical to the second question of the WHO ASSIST 
questionnaire.13 A categorical variable for the frequency of past-year cannabis use was 
defined as none (“never”), less than daily (“less than monthly”, “monthly” and “weekly”) 
and daily (“daily or almost daily”). Any response other than ‘never’ was considered positive 
for any past-year cannabis use. The term ‘marijuana’ was used in the question as it is the 
most commonly used U.S. cannabis term.14 Marijuana use was not defined and could 
include nonmedical and medical use.
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Additional Behavioral Health Screen items: The 7-item screen also included the 2-item 
Patient Health Questionnaire (PHQ-2) to assess possible depression in the past two weeks 
(item scores 0–3; scores of 2 or 3 were positive for depression)15 and the 3-item Alcohol 
Use Disorders Identification Test–Consumption (AUDIT-C) questionnaire to assess 
unhealthy alcohol use in the past year (total scores of ≥3 for women and ≥4 for men were 
positive for unhealthy alcohol use).16 A single-item screen for frequency of past-year illicit 
drug use or nonmedical use of prescription medication, which followed the cannabis screen, 
was adapted from a validated screen11 and had response options identical to the cannabis 
screen, with any response other than ‘never’ positive for past-year illicit drug use/medication 
misuse. In the uncommon case that a patient completed the 7-item screen more than once 
during the study period (2.4% of patients), the highest score for each condition-specific 
screen, if different, was used.
Demographic and Other Behavioral Health Conditions—Gender (women/men), 
age (18–29, 30–49, 50–64, ≥65), race/ethnicity (black, Hispanic, other, white, unknown)17 
were extracted from the EHR at the time of each patient’s initial in-person visit to the sites 
during the study period. Behavioral health characteristics were selected based on their 
association with cannabis use. Current tobacco use was based on any EHR documentation in 
the year prior to initial visit that the patient reported currently using tobacco. Diagnostic 
codes based on ICD-9-CM (prior to October 1, 2015) and ICD-10-CM (as of October 1, 
2015) documentation in the EHR by providers for conditions addressed or considered during 
an encounter were used to classify mental health and substance use disorders recognized in 
the year prior to the cannabis screen. Mental health disorders in the past year were 
categorized into major depressive disorders, anxiety disorders, including generalized 
anxiety, panic, phobias and PTSD, and serious mental illness, including schizophrenia, 
bipolar disorder and psychosis. Substance use disorders in the past year were categorized 
into alcohol use disorders, cannabis use disorders and other drug use disorders (i.e., does not 
include nicotine, alcohol or cannabis). Consistent with the use of the cannabis use question 
as routine clinical assessment of the frequency of use (i.e., not as a diagnostic tool for a 
disorder), patients with a cannabis use disorder were included in the study. Composite 
indicators for any mental health disorder (e.g., depression, anxiety, serious mental illness) 
and any non-cannabis substance use disorder (e.g., alcohol and other drug use disorders) 
were also evaluated.
Analyses
Analyses described sample characteristics, including the prevalence and frequency of past-
year cannabis use. The prevalence and frequency of past-year cannabis use, along with 95% 
confidence intervals, were also calculated among patient subgroups based on demographic 
(e.g., patients within each category of gender, age, and race/ethnicity) and behavioral health 
(e.g., patients who screened positive on a behavioral health screen or had documentation of a 
behavioral health condition/diagnosis) characteristics.1 All analyses were conducted in Stata 
Version 13.1 MP edition.
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RESULTS
A total of 29,857 patients visited the 3 primary care sites during the study period, and of 
those, 22,095 (74.0%) patients had EHR documentation of the question about past-year 
cannabis use and were included in the study sample. Among patients who made a visit, those 
who completed the cannabis use question were similar to those who did not (data available 
upon request).
Most patients in the study sample were female, white and older; 9.7% reported current 
tobacco use and 15.0% had a major depression diagnosis in the past year [Table 2]. Among 
patients in the sample, 15.3% (95% CI 14.8%–15.8%) reported any cannabis use in the past 
year: 7.7% (7.3%–8.0%) less than monthly; 2.2% (2.0%-2.4%) monthly; 2.3% (2.1%–2.5%) 
weekly; and 3.1% (2.9%–3.3%) daily. Among those who reported any cannabis use, 50.1% 
(48.4%–51.8%) reported infrequent use (<monthly), 14.6% (13.5%–15.9%) and 15.0% 
(13.8%–16.2%) reported monthly and weekly use, respectively, and 20.3% (19.0%–21.7%) 
reported daily use.
The prevalence and frequency of past-year cannabis use was high among men and patients 
18–29 years old [Figure 1 Panel A]. In particular, 32.1% (29.7%–34.5%) of women 18–29 
years reported any cannabis use and 6.1% (4.9%–7.4%) reported daily use, while 43.6% 
(40.1%–47.2%) of men 18–29 years reported any cannabis use and 12.1% (9.7%–14.4%) 
daily use.
Compared to the prevalence among all primary care patients, any and daily past-year 
cannabis use was higher among patients in each behavioral health subgroup [Figure 1 Panel 
B]. Among 5,340 patients with a mental health disorder, 18.9% (17.9%–20.0%) and 4.5% 
(3.9%-5.0%) reported any and daily past-year cannabis use, respectively, while among 558 
patients with a non-cannabis substance use disorder, 31.0% (27.3%–35.0%) and 8.4% 
(6.4%–11.0%) reported any and daily past-year cannabis use, respectively. Among 109 
patients with a cannabis use disorder documented in the past year, 84.4% (76.3%–90.1%) 
and 49.5% (40.2%–58.9%) reported any and daily past-year use, respectively.
When patient characteristics were combined, the prevalence of cannabis use was higher in 
some groups [Table 3; Appendix A]. For example, among men 18–29 years who screened 
positive for depression or reported tobacco use, 63.0% (55.6%–70.4%) and 65.8% (57.3%–
74.4%), respectively, reported any cannabis use, with 25.5% (18.8%–32.1%) and 31.7% 
(23.3%–40.0%), respectively, reporting daily use.
To identify patient characteristics independently associated with increased odds of past-year 
cannabis use, two post-hoc logistic regressions, with binary outcomes for any use and daily 
use, were performed and adjusted for all measured patient demographic and clinical 
characteristics.18 The adjusted odds of any use were higher among patients who were male, 
younger, current tobacco users, or had depression, anxiety, unhealthy alcohol use, or illicit 
drug use/prescription medication misuse, with similar results for daily use (Table 4). Patients 
18–29 years had the highest adjusted odds of any use and daily use, 7.34 (6.42–8.40) and 
4.82 (3.67–6.31), respectively, when compared to patients 65 years and older.
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DISCUSSION
More than 1 in 6 primary care patients in a state where cannabis use is legal reported using 
cannabis when screened for depression, unhealthy alcohol use, cannabis and illicit drug use 
as part of routine behavioral health screening. Cannabis use was particularly common 
among young adults—nearly 4 in 10 reported past-year use—and among those with tobacco 
use, unhealthy alcohol use, illicit drug use, or mental health or substance use disorders. 
Daily cannabis use was reported by 1 in 12 young adults and nearly 1 in 20 patients with a 
mental health disorder. However, when multiple characteristics associated with use were 
combined (e.g. young men who used tobacco or screened positive for depression), the 
prevalence of daily use exceeded 25%. These relationships persisted after adjustment, with 
younger patients and those with other substance use and behavioral health concerns having 
higher adjusted odds of any and daily cannabis use.
As states legalize use of cannabis, the perception that cannabis use is safe has increased.19,20 
However, frequent and/or high-potency cannabis use—irrespective of the purpose—
increases the risk of cannabis use disorder. Moreover, the concentration of 
tetrahydrocannabinol (THC), the main psychoactive and addictive component in cannabis, 
has increased in cannabis plants from an average of 3% to 12% in recent years, with some in 
excess of 20%, contributing to a higher prevalence of cannabis use disorders.21 New 
methods of administration and new products, including concentrated hash oil, synthetic 
cannabinoids and edibles, have further increased the per-use potency of cannabis and the risk 
of addiction.22,23 More than 9% of lifetime cannabis users will develop and 25%–50% 
patients who use daily are at risk for a cannabis use disorder.3,24,25 Young adults have the 
greatest risk, with 35% of current users meeting criteria for a cannabis use disorder.26 Young 
adults may also be most adversely impacted, as frequent use diminishes educational, 
occupational, cognitive and social development.27,28 Patients who use cannabis for medical 
purposes, the majority of whom also use recreationally, are more likely to use multiples 
times per day and to use highly potent forms of cannabis to manage symptoms.8 All of these 
factors increase the risk that patients who use cannabis will develop a cannabis use disorder.
Cannabis use poses other significant health risks, which increase with the frequency and 
intensity of use: 1) central nervous system impairment, acute (e.g., judgment, coordination) 
and chronic (e.g., memory, cognition),29 2) exacerbation and persistence of psychiatric 
symptoms (e.g., depression, psychosis),30 3) development of other drug use disorders, 
including nicotine and alcohol31 4) prescription medication interactions (e.g., 
antidepressants, opioids),32 5) prenatal exposure during pregnancy,33 6) pulmonary 
symptoms29 and 7) accidents, particularly motor vehicle accidents.34 Finally, frequent use of 
cannabis can cause significant withdrawal, which appears clinically similar to tobacco and 
opioid withdrawal, with symptoms of anxiety, irritability, depressed mood, disturbed sleep, 
decreased appetite and restlessness.35
Although cannabis use has established health risks, the U.S. Preventive Services Task Force 
does not currently recommend routine preventive screening for cannabis or other illicit drug 
use in primary care due to the lack of known effective brief primary care interventions to 
decrease drug use.36 However, the value of asking about cannabis use, separate from brief 
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interventions, has not been investigated. Results of this study suggest primary care patients 
are willing to report cannabis use, including daily use, as part of behavioral health screening 
documented in their EHRs.
Knowledge of patients’ cannabis use could help providers initiate conversations with 
patients, allowing for assessment of the reasons, perceived risks/benefits, and intensity of 
cannabis use. While cannabis may have therapeutic value for promoting appetite and treating 
nausea, spasticity, chronic pain, and neuropathic pain, providers may want to advise patients 
about more effective and/or safer treatment alternatives available for most conditions.27,37 
Additionally, there is inadequate evidence for the efficacy of cannabis use for some 
conditions/symptoms, like depression and anxiety, which can be worsened by cannabis 
use.38 Because of the potential for harm, women should be advised against cannabis use 
during pregnancy.39
For patients who use cannabis regularly, assessment of the intensity (e.g., frequency per-day, 
method of administration) and potency of use, as well as symptoms of a cannabis use 
disorder using questionnaires like the Cannabis Use Disorders Identification Test40 or 
DSM-5 substance use disorder criteria,41 can provide additional information about a 
patient’s risk for cannabis-related consequences, including addiction. For patients who have 
a cannabis use disorder, cognitive behavioral and motivational enhancement therapies are 
effective, separately and in combination, in reducing cannabis use and the severity of 
disorder symptoms.42,43 Contingency management can augment treatment outcomes when 
paired with these therapies.42,43 No medication has proven broadly effective nor been 
approved for treatment of cannabis use disorders.42 Most pharmacotherapies evaluated, 
including antidepressants, bupropion, buspirone, and atomoxetine, have shown little value in 
treating cannabis use disorders.44 Although gabapentin, N-acetylcysteine (NAC), especially 
NAC for 18–21 year olds,45 and medications containing THC have shown promise, further 
investigation is needed. As most patients with a cannabis use disorder will not seek care in 
formal treatment settings,1,46 behavioral and other effective treatments for cannabis use 
disorders in primary care are needed.
There are several limitations to this study. Although the question about cannabis use was 
adapted from well-validated alcohol and substance use measures, it has not been validated 
against a gold-standard interview for cannabis use. However, the question has high face 
validity, and underreporting is expected,47 making estimates of the prevalence of any 
cannabis use in this study (15%) conservative. The prevalence of cannabis use in this study 
is higher than the national prevalence (12.5%),1 consistent with findings that the prevalence 
of use is higher in states with legalized use.48 Furthermore, the frequency of cannabis use 
among young adults in this sample of Washington State primary care patients is comparable 
to that reported by young adults in the same state on a 2014 confidential internet-based 
survey.19 Although there was no evidence of selective non-response, a quarter of eligible 
patients did not complete behavioral health screening. Reasons included that medical 
assistants did not offer the screen (e.g., were busy or staffing was low), patients did not 
speak/read English, or the primary care provider was behind schedule. The prevalence of 
cannabis and other substance use disorders in this study, based on documentation by 
clinicians in the EHR in the previous year, was low compared to US population 
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estimates,26,49 in contrast to rates for mental health diagnoses,50 suggesting under-
recognition of substance use disorders. Research is needed to determine whether routine 
assessment of cannabis and other drug use as part of behavioral health screening increases 
the prevalence of recognized substance use disorders. Although a question about frequency 
of past-year cannabis use was practical for routine screening, the question omitted relevant 
dimensions of use (e.g., potency, frequency per-day, medical vs. nonmedical use). Future 
studies of cannabis use among primary care patients need to assess differences in medical 
and nonmedical use and the intensity, potency and methods of cannabis used. Finally, this 
study was restricted to adults and similar research is needed on younger patients.
In summary, this study of the prevalence and frequency of cannabis use among primary care 
patients, in a state with legalized use, found that most primary care patients who completed 
recommended routine behavioral health screening (e.g., depression and alcohol),51,52 also 
completed a question about past-year cannabis use. Additionally, while 15% of all primary 
care patients reported any past-year cannabis use, the prevalence was much higher in 
important patient subgroups. Most notably, more than 1 in 4 younger men who used tobacco 
or screened positive for depression reported high-risk daily cannabis use. Routinely asking 
about cannabis use could promote recognition of patients who may benefit from primary 
care discussions about their cannabis use.
Acknowledgments
Author Contributions: Dr. Lapham had full access to all the study data and takes responsibility for the integrity of 
the data and the accuracy of the data analysis. Study concept and design: Lapham, Bradley. Statistical analysis: 
Lapham. Interpretation of results: All authors. Drafting of manuscript: Lapham, Bradley. Critical revision of the 
manuscript for important intellectual content: All authors.
Funding/Support: Awards from the National Institute on Drug Abuse (UG1DA040314-01S1, UG1 DA01581) and 
the Agency for Healthcare Research and Quality (R18 HS023173) supported study implementation, analysis and 
manuscript preparation.
Role of the Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, 
analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit 
the manuscript for publication.
Prior Presentations: This paper has not been presented at any conference.
References
1. National Survey on Drug Use and Health (NSDUH). [Accessed October 1, 2015] Results from the
2013 National Survey on Drug Use and Health: Summary of National Findings and Detailed Tables.
2015. http://archive.samhsa.gov/data/NSDUH/2013SummNatFindDetTables/Index.aspx
2. Hasin DS, O'Brien CP, Auriacombe M, et al. DSM-5 Criteria for Substance Use Disorders:
Recommendations and Rationale. Am J Psychiatry. 2013; 170(8):834–851. [PubMed: 23903334]
3. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States
Between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015; 72(12):1235–1242. [PubMed:
26502112] 
4. Moss HB, Chen CM, Yi HY. Measures of substance consumption among substance users, DSM-IV
abusers, and those with DSM-IV dependence disorders in a nationally representative sample. J Stud
Alcohol Drugs. 2012; 73(5):820–828. [PubMed: 22846246]
5. Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the
USA. Clin Pharmacol Ther. 2015; 97(6):607–615. [PubMed: 25777798]
Lapham et al. Page 8
J Am Board Fam Med. Author manuscript; available in PMC 2018 January 16.
6. Prescription Drug Abuse Policy System. [Accessed March 30, 2016] Medical Marijuana Laws for
Patients. 2016. Available from: http://www.pdaps.org/dataset/overview/medical-marijuana-patient-
related-laws/56e5ad5bd42e0723743aa700
7. Pew Research Center. [Accessed November 30, 2015] Majority Now Supports Legalizing
Marijuana. 2013. http://www.people-press.org/2013/04/04/majority-now-supports-legalizing-
marijuana/
8. Pacula RL, Jacobson M, Maksabedian EJ. In the weeds: a baseline view of cannabis use among
legalizing states and their neighbours. Addiction. 2016; 111(6):973–980. [PubMed: 26687431]
9. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid Dose and
Label Accuracy in Edible Medical Cannabis Products. JAMA. 2015; 313(24):2491–2493. [PubMed:
26103034] 
10. Kleiman, M. A Cannabis Research Agenda for Policy Design: What do we need to know?. Paper
presented at: Marijuana and Cannabinoids: A Neuroscience Research Summit; 2016; Bethesda,
MD.
11. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug
use in primary care. Arch Intern Med. 2010; 170(13):1155–1160. [PubMed: 20625025]
12. Babor, TF., Higgins-Biddle, JC., Saunders, JB., Monteiro, MG. [Accessed Feb 1, 2012] AUDIT:
The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. 22001. http://
www.dass.stir.ac.uk/DRUGS/pdf/audit.pdf
13. WHO Assist Working Group. The Alcohol, Smoking and Substance Involvement Screening Test
(ASSIST): development, reliability and feasibility. Addiction. 2002; 97(9):1183–1194. [PubMed:
12199834] 
14. Ruschmann, P. Legalizing Marjiuana. New York, NY: Chelsea House; 2004.
15. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item
depression screener. Med Care. 2003; 41(11):1284–1292. [PubMed: 14583691]
16. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief
screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007; 31(7):1208–1217.
[PubMed: 17451397]
17. Williams EC, Lapham GT, Hawkins EJ, et al. Variation in documented care for unhealthy alcohol
consumption across race/ethnicity in the Department of Veterans Affairs Healthcare System.
Alcohol Clin Exp Res. 2012; 36(9):1614–1622. [PubMed: 22404130]
18. Janes H, Pepe MS. Adjusting for covariates in studies of diagnostic, screening, or prognostic
markers: an old concept in a new setting. Am J Epidemiol. 2008; 168(1):89–97. [PubMed:
18477651] 
19. Center for the Study of Health and Risk Behaviors, University of Washingtion. [Accessed May 3,
2016] Young Adult Health Survey: Marijuana. 2015. Available from: http://
learnaboutmarijuanawa.org/factsheets/YAHS%20Marijuana.pdf
20. Pacek LR, Mauro PM, Martins SS. Perceived risk of regular cannabis use in the United States from
2002 to 2012: differences by sex, age, and race/ethnicity. Drug Alcohol Depend. 2015; 149:232–
244. [PubMed: 25735467]
21. Sevigny EL, Pacula RL, Heaton P. The effects of medical marijuana laws on potency. Int J Drug
Policy. 2014; 25(2):308–319. [PubMed: 24502887]
22. Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav.
2014; 39(10):1430–1433. [PubMed: 24930049]
23. Lee DC, Crosier BS, Borodovsky JT, Sargent JD, Budney AJ. Online survey characterizing
vaporizer use among cannabis users. Drug Alcohol Depend. 2016; 159:227–233. [PubMed:
26774946] 
24. Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence,
correlates and co-morbidity. Psychol Med. 2006; 36(10):1447–1460. [PubMed: 16854249]
25. Haberstick BC, Young SE, Zeiger JS, Lessem JM, Hewitt JK, Hopfer CJ. Prevalence and correlates
of alcohol and cannabis use disorders in the United States: results from the national longitudinal
study of adolescent health. Drug Alcohol Depend. 2014; 136:158–161. [PubMed: 24440049]
Lapham et al. Page 9
J Am Board Fam Med. Author manuscript; available in PMC 2018 January 16.
26. Hasin DS, Kerridge BT, Saha TD, et al. Prevalence and Correlates of DSM-5 Cannabis Use
Disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related
Conditions-III. Am J Psychiatry. 2016; 173(6):588–599. [PubMed: 26940807]
27. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl
J Med. 2014; 370(23):2219–2227. [PubMed: 24897085]
28. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and
executive function. Psychol Addict Behav. 2012; 26(3):496–506. [PubMed: 22103843]
29. Schrot RJ, Hubbard JR. Cannabinoids: Medical implications. Ann Med. 2016; 48(3):128–141.
[PubMed: 26912385]
30. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective
mental health outcomes: a systematic review. Lancet. 2007; 370(9584):319–328. [PubMed:
17662880] 
31. Blanco C, Hasin DS, Wall MM, et al. Cannabis Use and Risk of Psychiatric Disorders: Prospective
Evidence From a US National Longitudinal Study. JAMA Psychiatry. 2016; 73(4):388–395.
[PubMed: 26886046]
32. Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and
analgesia. Curr Opin Pharmacol. 2010; 10(1):80–86. [PubMed: 19857996]
33. Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child
health outcomes: a systematic review and meta-analysis. BMJ Open. 2016; 6(4):e009986.
34. Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and
revised. Addiction. 2016; 111(8):1348–1359. [PubMed: 26878835]
35. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale
development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend.
2011; 119(1–2):123–129. [PubMed: 21724338]
36. Polen, MR., Whitlock, EP., Wisdom, JP., Nygren, P., Bougatsos, C. Screening in Primary Care
Settings for Illicit Drug Use: Staged Systematic Review for the U.S. Preventive Services Task
Force. Rockville, MD: AHRQ; Jan. 2008
37. Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric
Problems: A Clinical Review. JAMA. 2015; 313(24):2474–2483. [PubMed: 26103031]
38. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review
and Meta-analysis. JAMA. 2015; 313(24):2456–2473. [PubMed: 26103030]
39. Volkow ND, Compton WM, Wargo EM. The Risks of Marijuana Use During Pregnancy. JAMA.
2017; 317(2):129–130. [PubMed: 27992628]
40. Adamson SJ, Kay-Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse:
the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depend. 2010;
110(1–2):137–143. [PubMed: 20347232]
41. Saha TD, Compton WM, Chou SP, et al. Analyses related to the development of DSM-5 criteria for
substance use related disorders: 1. Toward amphetamine, cocaine and prescription drug use
disorder continua using Item Response Theory. Drug Alcohol Depend. 2012; 122(1–2):38–46.
[PubMed: 21963414]
42. Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. Psychiatr Clin
North Am. 2012; 35(2):309–326. [PubMed: 22640758]
43. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use
disorder. Cochrane Database Syst Rev. 2016; 5(5):CD005336.
44. Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane
Database Syst Rev. 2014; 12(12):CD008940.
45. Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-
acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012; 169(8):805–812.
[PubMed: 22706327]
46. McLellan AT. Public accountability in addiction treatment. Lancet. 2009; 374(9697):1220–1221.
[PubMed: 19819374]
47. Korthuis, PT., Burdick, T., Leed, R., Payment, M., Kunkel, LE., McCarty, D. Using An Electronic
Health Record Communication Tool To Assess Patient Attitudes Toward Cannabis Use. Paper
presented at: American Society of Addiction Medicine Annual Conference; 2016; Baltimore, MD.
Lapham et al. Page 10
J Am Board Fam Med. Author manuscript; available in PMC 2018 January 16.
48. Cerda M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating
the relationship between state legalization of medical marijuana and marijuana use, abuse and
dependence. Drug Alcohol Depend. 2012; 120(1–3):22–27. [PubMed: 22099393]
49. Grant BF, Saha TD, Ruan WJ, et al. Epidemiology of DSM-5 Drug Use Disorder: Results From the
National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry. 2016;
73(1):39–47. [PubMed: 26580136]
50. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care:
prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007; 146(5):317–325.
[PubMed: 17339617]
51. U S. Preventive Services Task Force. Screening and behavioral counseling interventions in primary
care to reduce alcohol misuse: recommendation statement. Ann Intern Med. 2004; 140(7):554–
556. [PubMed: 15068984]
52. U S. Preventive Services Task Force. Screening for depression in adults: U.S. preventive services
task force recommendation statement. Ann Intern Med. 2009; 151(11):784–792. [PubMed:
19949144] 
Appendix A. The prevalence and frequency of past-year cannabis use 
among patient demographic and behavioral health subgroups
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Appendix B. Among young patients 18–29 years old with a documented 
condition, diagnosis or behavioral health screen, the prevalence of past-
year cannabis use
Note. Any use is the summed total of <monthly/monthly/weekly use and daily use. 
Documented conditions and diagnoses were in the year prior to the clinic visit
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Figure 1. 
The prevalence of past-year cannabis use among patients in age and gender subgroups (panel 
A) and among those with a documented condition, diagnosis or behavioral health screen
(panel B)
Note. Any use is the summed total of <monthly/monthly/weekly use and daily use. 
Documented conditions and diagnoses were in the year prior to the clinic visit
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Table 2
















Tobacco use* 2,133 (9.7)
Diagnoses in prior year*
Major depression 3,323 (15.0)
Anxiety disorder 2,994 (13.6)
Serious mental illness‡ 704 (3.2)
Alcohol use disorder 396 (1.8)
Cannabis use disorder 109 (0.5)
Other drug use disorder 200 (0.9)
Behavioral health screens
Depression (PHQ-2) ‡ 3,582 (16.3)
Unhealthy alcohol use‡ 5,863 (26.6)
Any illicit drug use/Rx drug misuse‡ 363 (1.7)
*
Assessed in the year prior to clinic visit
†
Includes diagnoses for bipolar disorder, psychosis and schizophrenia
‡
Total N varies due to some patients not completing items of Behavioral Health screen: PHQ-2 (n 22,081); AUDIT-C (n 22,034); drug screen (n 
21,945)
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